Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PIKA Influenza Vaccine
- Development stage
- Preclinical
- Lead developer
- LakeShore Biopharma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Injection
01
Overview
The PIKA Influenza Vaccine is an adjuvanted vaccine candidate being developed by LakeShore Biopharma (formerly YS Biopharma/Lakenord) for the prevention and treatment of influenza virus infections. It utilizes the proprietary PIKA adjuvant platform, which consists of a stabilized double-stranded RNA (dsRNA) molecule. This adjuvant acts as a Toll-like receptor 3 (TLR3) agonist, stimulating the innate immune system and enhancing both humoral and cellular adaptive immune responses to influenza antigens. The vaccine is designed to provide broad-spectrum protection and improved immunogenicity compared to non-adjuvanted vaccines. It is currently in the preclinical stage of development.
- Other names
- PIKA adjuvanted influenza vaccine
02
Targets
TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on PIKA Influenza Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PIKA Influenza Vaccine.